PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre™

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

Zepsyre^™ is currently undergoing development for the treatment of solid tumours. This promising agent is currently in final stage for platinum-resistant ovarian cancer and small cell lung cancer. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), as regulatory agencies, require the trade name to be unique and is part of the evaluation and approval process before marketing the product.

After the positive results presented during the last ESMO and ASCO meetings about BRCA 2 -associated metastatic breast cancer and endometrial cancer, respectively, PharmaMar will initiate a pivotal phase III study in each indication.  

"We trust in the potential of Zepsyre^™ as a therapeutic alternative due to its novel mechanism of action and the antitumoral activity observed in all clinical trials for different type of tumors," says Luis Mora, Managing Director Oncology Business Unit at PharmaMar.

About Zepsyre™ (PM1183)

Zepsyre™ is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

About PharmaMar  

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS^® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com

Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)

SOURCE PharmaMar